Edition:
United Kingdom

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

229.20USD
16 Feb 2018
Change (% chg)

$0.07 (+0.03%)
Prev Close
$229.13
Open
$228.85
Day's High
$230.88
Day's Low
$227.15
Volume
302,521
Avg. Vol
345,102
52-wk High
$248.81
52-wk Low
$158.12

Chart for

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $29,871.53
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 148.59 16.64
EPS (TTM): -- -- --
ROI: -- 9.38 10.66
ROE: -- 14.72 14.30

BRIEF-Illumina Q4 GAAP Earnings Per Share $0.46

* ILLUMINA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2017

30 Jan 2018

BRIEF-Illumina Awarded $26.7 Mln In Patent Suit Against Ariosa Diagnostics

* ILLUMINA AWARDED $26.7M IN PATENT SUIT AGAINST ARIOSA DIAGNOSTICS, INC.

26 Jan 2018

Illumina wins $26.7 million in patent fight with Roche unit Ariosa

Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

25 Jan 2018

UPDATE 1-Illumina wins $26.7 mln in patent fight with Roche unit Ariosa

Jan 25 Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

25 Jan 2018

Illumina wins $26.7 million in patent fight with Roche unit Ariosa

Jan 25 Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

25 Jan 2018

BRIEF-Premaitha Health Says Secured Right To Appeal First Instance Judgment

* HAS SECURED RIGHT TO APPEAL A FIRST INSTANCE JUDGMENT IN ITS ONGOING LITIGATION WITH ILLUMINA INC. AND OTHERS

24 Jan 2018

BRIEF-Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018

* ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018

11 Jan 2018

BRIEF-Guangzhou Kingmed Diagnostics' Unit Signs Agreement With U.S. company Illumina

Jan 8 Guangzhou Kingmed Diagnostics Group Co Ltd :

08 Jan 2018

BRIEF-HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement

* HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT

27 Dec 2017

BRIEF-Luna Dna Announces $2 Mln In Seed Funding Round Included Several Individual Investors And Former Executives From Illumina

* LUNA DNA ANNOUNCES $2 MILLION IN SEED FUNDING; ROUND INCLUDED SEVERAL INDIVIDUAL INVESTORS AND FORMER EXECUTIVES FROM ILLUMINA Source text for Eikon: Further company coverage:

18 Dec 2017

Earnings vs. Estimates